Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference call by phone, use the following conference call registration link.

Novocure to Report Second Quarter 2024 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These data will be presented at the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The METIS trial enrolled 298 adult patients with 1-10 brain metastases from NSCLC, who we.

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routi.

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

Arrowhead Pharmaceuticals

Joby Aviation

Matthews International

Navitas Semiconductor Corp

Viking Therapeutics

YETI

If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025

NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago.

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocur.

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “The first quarter was a period of strong execution,” said William Doyle, Novocure's Executive Chairman. “In Q1, GBM active patients grew 11%, we announced the METI.

Novocure Reports First Quarter 2024 Financial Results

NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NS.

Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, include new insights on how TTFields therapy can potentially enhance the immune system's ability to combat cancer cells and on TTFields therapy's effects and mechanisms in.

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, use the following conference call registration link and dial-in.

Novocure to Report First Quarter 2024 Financial Results

Novocure announced encouraging results from a phase 3 study of its TTFields therapy in treating brain metastases. The therapy previously failed to reach a primary endpoint in a separate study for treating platinum-resistant ovarian cancer.

Why NovoCure Stock Soared 18.3% This Week

Novocure announced results from a phase 3 study of its TTFields therapy in treating brain metastases. Patients treated with TTFields experienced a significant improvement in the median time to intracranial progression.

Why Novocure Stock Is Jumping Today

NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?

Novocure Ltd.'s stock soared 15% Wednesday after the company announced positive results from a late-stage trial of a medtech device to treat patients with lung cancer that has spread to their brains.

Novocure's stock surges after positive results in brain-cancer trial

Novocure (NASDAQ:NVCR) shares soared on Wednesday as the oncology firm revealed its investigational medical device slowed the spread of cancer to the brain in patients with lung cancer during a late-stage trial. The Phase 3 METIS trial evaluated NovoCure's Tumor Treating Fields (TTFields) therapy - a device that uses electric fields that exert physical forces to kill cancer cells via various mechanisms - in combination with supportive care in patients with 1 to 10 brain metastasis from non-small cell lung cancer following stereotactic radiosurgery.

NovoCure device slows spread of lung cancer to brain in late-stage study; shares rise

Zai Lab Ltd.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) partner Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cance.

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Novocure stock surged Wednesday after its medtech device nearly doubled the length of time patients with brain tumors lived before worsening.

Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment

Novocure said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer.

Novocure's lung cancer therapy succeeds in late-stage trial

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer (NSCLC) following stereotactic radiosurgery (SRS). Patients.

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

The mean of analysts' price targets for NovoCure (NVCR) points to a 63.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3) clinical trial has been selected for presentation at the “Best Oral Session – Late Breaking Abstracts” on Sunday, March 10, 2024 at the European Society on Gynaecological Oncology (ESGO) 2024 Congress in Barcelona. The randomized, phase 3 INNOVATE-3 clinical trial evaluate.

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript

NovoCure (NVCR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.36 per share a year ago.

News for Novocure Stock (NVCR)